As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.
10 Analysts have issued a Caris Life Sciences forecast:
10 Analysts have issued a Caris Life Sciences forecast:
Mar '25 |
+/-
%
|
||
Revenue | 121 121 |
50%
50%
|
|
Gross Profit | 57 57 |
119%
119%
|
|
EBITDA | -51 -51 |
32%
32%
|
EBIT (Operating Income) EBIT | -58 -58 |
37%
37%
|
Net Profit | -127 -127 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Caris Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Head office | United States |
Website | www.carislifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.